Breaking News, Financial News

Valneva FY Revenues Climb 216%

Growth attributable to revenues from terminated UK COVID-19 vaccine supply agreement for non-refundable payments received for duration of the contract.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Valneva FY Revenues: €348.1 million (+216%) Comments: Product sales decreased by 4.5% to €63.0 million in 2021 as the travel industry continued to be impacted by the COVID-19 pandemic. IXIARO/JESPECT sales decreased by 6.9% to €45.1 million. DUKORAL sales declined by 81.7% to €2.4 million in 2021. Third Party product sales grew by 271.3% to €15.4 million in 2021 driven by incremental sales related to Valneva’s distribution agreement with Bavarian Nordic for the sales of Rabipur/RabAvert and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters